Drugmaker Urges Full Fed. Circ. To Kill USPTO Fee Rule
A drugmaker challenging the U.S. Patent and Trademark Office's controversial new policy on attorneys' fees urged the full Federal Circuit on Tuesday to rule that the novel approach is a violation...To view the full article, register now.
Already a subscriber? Click here to view full article